Premium
Pharmacological priming of adipose‐derived stem cells for paracrine VEGF production with deferoxamine
Author(s) -
Liu GueiSheung,
Peshavariya Hitesh M.,
Higuchi Masayoshi,
Chan Elsa C.,
Dusting Gregory J.,
Jiang Fan
Publication year - 2016
Publication title -
journal of tissue engineering and regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.835
H-Index - 72
eISSN - 1932-7005
pISSN - 1932-6254
DOI - 10.1002/term.1796
Subject(s) - deferoxamine , paracrine signalling , vascular endothelial growth factor , angiogenesis , pharmacology , stem cell , regenerative medicine , vascular endothelial growth factor a , wound healing , adipose tissue , microbiology and biotechnology , cancer research , chemistry , immunology , medicine , biology , vegf receptors , receptor
Adipose‐derived stem cells (ASCs) show great potentials in applications such as therapeutic angiogenesis, regenerative medicine and tissue engineering. Pharmacological preconditioning of stem cells to boost the release of cytoprotective factors may represent an effective way to enhance their therapeutic efficacy. In this study, the aim was to determine whether deferoxamine can enhance the release of vascular endothelial growth factor (VEGF) from in vitro expanded ASCs. It is demonstrated that deferoxamine (50–300 μ m ) upregulated VEGF expression in a concentration‐ and time‐dependent fashion. At the concentrations used, deferoxamine did not show any cytotoxic effects. The stimulatory effect of deferoxamine on VEGF expression was mediated by augmentation of hypoxia inducible factor‐1 in ASCs, but independent of its antioxidant properties. Moreover, deferoxamine enhanced the paracrine effects of ASCs in promoting the regenerative functions of endothelial cells (migration and in vitro wound healing activities). This study provides evidence that deferoxamine might be a useful drug with low cell toxicity for pharmacological preconditioning of ASCs to enhance their capacity of VEGF production. Copyright © 2013 John Wiley & Sons, Ltd.